Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9103

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Department of Defense (DoD), through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9103) seeking quotations from qualified pharmaceutical manufacturers for participation in the Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the DoD to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The primary objective of this solicitation is to obtain competitive quotes for pharmaceutical agents within specific drug classes that are under consideration for placement on the DoD Uniform Formulary (UF). The UF is a critical component of the MHS pharmacy benefits program, ensuring that military beneficiaries have access to clinically effective and cost-efficient medications. The DoD Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of pharmaceutical agents and makes recommendations regarding their inclusion in the UF, as well as their classification for cost-sharing purposes (e.g., generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary). For the February 2026 P&T Committee meeting, the following newly approved drugs will be reviewed for potential inclusion in the UF: - Hyrnuo (Lung Cancer - HER2+) - Javadin (Antihypertensive Agents) - Komzifti (Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia) - Lasix ONYU (Diuretics) - Redemplo (Antilipidemics-2) - Starjemza (Targeted Immunomodulatory Biologics - Interleukin 23) The solicitation includes the RFQ and appendices detailing the requirements for both the UF BPA and UF ADP agreements. Contractors are expected to provide comprehensive responses to clinical questions and submit competitive pricing proposals for the identified pharmaceutical agents. The process and evaluation criteria are outlined in the attached RFQ documents. A pre-quotation teleconference is scheduled for December 17, 2025, as detailed in Part 2.4 of the RFQ. Contractors are encouraged to participate to gain clarity on the requirements and submission process. Responses to clinical questions (Part 3.4) must be submitted via email to the designated point of contact by the deadline specified in Part 2.3.2. Key details for this opportunity include: - NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing, 2022) - Product Service Code: 6505 (Drugs and Biologicals) - Place of Performance: San Antonio, Texas, United States - Contracting Entity: Defense Health Agency (Federal Office) - Primary Contact: Tracy Banks ([email protected]) - Secondary Contact: Julia Trang ([email protected]) - Notice Status: Active - Response Due Date: January 5, 2026, 18:01 - Notice URL: https://sam.gov/opp/59668aba0f06468b9b087d55646270ec/view This solicitation represents a significant opportunity for pharmaceutical manufacturers specializing in the identified drug classes to partner with the DoD in supporting the health and readiness of military personnel and their families. Interested contractors should review the attached RFQ and associated documents carefully to ensure compliance with all submission requirements and deadlines. Participation in the pre-quotation teleconference is highly recommended for prospective offerors seeking to clarify any aspects of the solicitation. No set-aside requirements or special considerations are specified in the provided notice. All interested and qualified parties are encouraged to respond in accordance with the instructions outlined in the RFQ.
Documents11